ProjectR3500-AD-1798 – EINE RANDOMISIERTE, DOPPELBLINDE, PLACEBOKONTROLLIERTE PHASE-IIA-STUDIE ZUR BEWERTUNG DER…

Basic data

Acronym:
R3500-AD-1798
Title:
EINE RANDOMISIERTE, DOPPELBLINDE, PLACEBOKONTROLLIERTE PHASE-IIA-STUDIE ZUR BEWERTUNG DER WIRKSAMKEIT UND SICHERHEIT VON REGN3500 ALS MONOTHERAPIE UND REGN3500 IN KOMBINATION MIT DUPILUMAB BEI ERWACHSENEN PATIENTEN MIT MITTELSCHWERER BIS SCHWERER ATOPISCHER DERMATITIS
Duration:
4/2/2019 to 12/31/2020
Abstract / short description:
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF REGN3500 MONOTHERAPY AND COMBINATION OF REGN3500 PLUS DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE
ATOPIC DERMATITIS
Keywords:
atopic dermatitis
Atopische Dermatitis

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Tarrytown, New York, United States of America
Help

will be deleted permanently. This cannot be undone.